Narsoplimab

About Omeros

Founded in 1994, Omeros has evolved from a GPCR discovery pioneer into a commercial entity with a strategic focus on the complement system. Its key achievement is the FDA approval of OMIDRIA for cataract surgery, while its primary value drivers are the late-stage investigational drugs narsoplimab for HSCT-TMA and OMS906 for PNH. The company's strategy involves prioritizing these high-potential clinical programs, seeking regulatory approvals and partnerships, and managing its significant debt burden to achieve sustainable growth.

About Omeros

Founded in 1994, Omeros has evolved from a GPCR discovery pioneer into a commercial entity with a strategic focus on the complement system. Its key achievement is the FDA approval of OMIDRIA for cataract surgery, while its primary value drivers are the late-stage investigational drugs narsoplimab for HSCT-TMA and OMS906 for PNH. The company's strategy involves prioritizing these high-potential clinical programs, seeking regulatory approvals and partnerships, and managing its significant debt burden to achieve sustainable growth.

Therapeutic Areas